Mitochondrial neurogastrointestinal encephalomyopathy (MNGIE) is a fatal, recessive disease caused by mutations in the gene encoding thymidine phosphorylase, leading to reduced enzymatic activity, toxic nucleoside accumulation, and secondary mitochondrial DNA damage. Thymidine phosphorylase replacement has been achieved by allogeneic hematopoietic stem cell transplantation, a procedure hampered by high mortality. Based on high thymidine phosphorylase expression in the liver, a 25-year-old severely affected patient underwent liver transplantation. Serum levels of toxic nucleosides rapidly normalized. At 400 days of follow-up, the patient's clinical conditions are stable. We propose liver transplantation as a new therapy for MNGIE.
Liver transplantation for mitochondrial neurogastrointestinal encephalomyopathy
DE GIORGIO, ROBERTO;PIRONI, LORIS;BOSCHETTI, ELISA;CAPORALI, LEONARDO;CAPRISTO, MARIANTONIETTA;CENACCHI, GIOVANNA;CONTIN, MANUELA MARIA ANTONIA;D'ANGELO, ROBERTO;D'ERRICO, ANTONIETTA;GRAMEGNA, LAURA LUDOVICA;LODI, RAFFAELE;MARESCA, ALESSANDRA;MOHAMED, SUSAN;PAPA, VALENTINA;TONON, CATERINA;TUGNOLI, VITALIANO;CARELLI, VALERIO;PINNA, ANTONIO DANIELE
2016
Abstract
Mitochondrial neurogastrointestinal encephalomyopathy (MNGIE) is a fatal, recessive disease caused by mutations in the gene encoding thymidine phosphorylase, leading to reduced enzymatic activity, toxic nucleoside accumulation, and secondary mitochondrial DNA damage. Thymidine phosphorylase replacement has been achieved by allogeneic hematopoietic stem cell transplantation, a procedure hampered by high mortality. Based on high thymidine phosphorylase expression in the liver, a 25-year-old severely affected patient underwent liver transplantation. Serum levels of toxic nucleosides rapidly normalized. At 400 days of follow-up, the patient's clinical conditions are stable. We propose liver transplantation as a new therapy for MNGIE.File | Dimensione | Formato | |
---|---|---|---|
DeGiorgio_2016_AM.pdf
accesso aperto
Tipo:
Postprint
Licenza:
Licenza per Accesso Aperto. Altra tipologia di licenza compatibile con Open Access
Dimensione
1.43 MB
Formato
Adobe PDF
|
1.43 MB | Adobe PDF | Visualizza/Apri |
I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.